EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

项目摘要/摘要 阿尔茨海默病(AD)是最普遍的神经退行性疾病，已造成全球重大 人口老龄化带来的健康问题。在不可逆转的脑损伤或精神损害之前早期诊断阿尔茨海默病 下降对于及时干预、对症治疗和改善患者功能至关重要。积累 研究表明，神经元来源的细胞外小泡(EV)是AD的重要生物标志物。然而， 研究人员在高效分离和准确分析电动汽车方面面临着重大挑战，限制了广泛的 EVS在AD早期诊断或靶向治疗中的研究与应用WellSIM建议开发和 基于我们革命性的出逃技术验证高吞吐量平台和工作流，以实现可靠和 从血浆和脑脊液中可重复地分离和分析EV，具有无与伦比的产量、纯度、产率和 敏感度。基于hi-exodus-NGS和hi-exodus-MS的综合分析、转录和蛋白质组学 将开发EVS图谱，以发现和检测EV衍生的多类生物标志物，用于AD诊断。

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However, researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.